HTBX Share Price | Scorpius Holdings, Inc. Stock Analysis & Recommendation

Q: How big is Scorpius Holdings, Inc.?

Market Cap: As of Jun 18, Scorpius Holdings, Inc. has a market capitalization of 0.50 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Scorpius Holdings, Inc. reported net sales of 6.24 million and a net profit of -34.33 million.Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds of 6.30 million and total assets amounting to 39.18 million.

Q: What does Scorpius Holdings, Inc. do?

Overview:Scorpius Holdings, Inc. is a development-stage immuno-oncology company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat various cancers, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: 1 Million (Quarterly Results - Dec 2024) Most recent Net Profit: -10 Million (Quarterly Results - Dec 2024) Market cap: USD 0.50 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 2.58 Return on Equity: -530.53% Price to Book: 0.08Contact Details:Address: 627 DAVIS DRIVE, SUITE 400, MORRISVILLE NC : 27560 Tel: 1 919 2407133 Fax: 1 302 6365454 Website: http://www.heatbio.com/

Q: Is Scorpius Holdings, Inc. overvalued or undervalued?

As of 13 November 2017, the valuation grade for Scorpius Holdings, Inc. moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its negative performance metrics, including a Price to Book Value of 0.08, an EV to EBITDA of -0.65, and a Return on Equity (ROE) of -530.53%. In comparison to its peers, Scorpius Holdings has a less favorable EV to EBITDA ratio than Lisata Therapeutics, Inc. at 0.1349 and Lipocine, Inc. at 0.3892, both of which are also classified as risky. The company's stock has dramatically underperformed against the S&P 500, with a year-to-date return of -99.61% compared to the index's 12.22%, reinforcing the notion that it is overvalued in the current market context.

Q: Is Scorpius Holdings, Inc. technically bullish or bearish?

As of 8 May 2025, the technical trend for Scorpius Holdings, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, driven by a bearish daily moving average and a bearish weekly KST. The MACD shows mildly bullish signals on both weekly and monthly time frames, while the RSI indicates a bearish weekly but bullish monthly trend. Bollinger Bands are sideways weekly and mildly bearish monthly. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -99.61% compared to the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Jun 2025)

FII

2.90%

Held by 7 FIIs

DII

96.92%

Held by 0 DIIs

Promoter

0.00%

How big is Scorpius Holdings, Inc.?

22-Jun-2025

As of Jun 18, Scorpius Holdings, Inc. has a market capitalization of 0.50 million, with net sales of 6.24 million and a net profit of -34.33 million over the last four quarters. The company has shareholder's funds of 6.30 million and total assets of 39.18 million as of Dec 24.

View full answer

What does Scorpius Holdings, Inc. do?

22-Jun-2025

Scorpius Holdings, Inc. is a development-stage immuno-oncology company focused on creating allogeneic, off-the-shelf cellular therapeutic vaccines for cancer treatment. It has a market cap of $0.50 million, with recent net sales of $1 million and a net loss of $10 million.

View full answer

Who are in the management team of Scorpius Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Scorpius Holdings, Inc. includes Mr. Jeffrey Wolf as Chairman, President, and CEO, Dr. John Prendergast as Lead Independent Director, and Dr. John Monahan and Mr. Edward Smith as Independent Directors.

View full answer

Is Scorpius Holdings, Inc. overvalued or undervalued?

20-Sep-2025

As of November 13, 2017, Scorpius Holdings, Inc. is classified as risky due to significant financial deterioration, overvaluation indicated by a Price to Book Value of 0.08, an EV to EBITDA of -0.65, a Return on Equity of -530.53%, and a year-to-date stock return of -99.61% compared to the S&P 500's 12.22%.

View full answer

Is Scorpius Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of May 8, 2025, Scorpius Holdings, Inc. shows a mildly bearish trend overall, with conflicting signals from technical indicators, including a bearish daily moving average and a year-to-date return of -99.61% compared to the S&P 500's 12.22%.

View full answer

Compare Scorpius Holdings, Inc. with Similar Stocks

Mangoceuticals, Inc.Edesa Biotech, Inc.Mustang Bio, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-5.64

Return on Equity

1,341.92%

Price to Book

-0.05

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-99.97%

6 Months

-99.97%

1 Year

-99.97%

2 Years

-99.99%

3 Years

-99.99%

4 Years

-99.98%

5 Years

-99.99%

Scorpius Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-1.98%

EBIT Growth (5y)

-28.10%

EBIT to Interest (avg)

-36.21

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

2.58

Sales to Capital Employed (avg)

0.22

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

8.30%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.08

EV to EBIT

-0.51

EV to EBITDA

-0.65

EV to Capital Employed

0.74

EV to Sales

2.69

PEG Ratio

Dividend Yield

ROCE (Latest)

-145.54%

ROE (Latest)

-530.53%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Mildly Bearish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 3 Schemes (0.18%)

Foreign Institutions

Held by 7 Foreign Institutions (2.9%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -80.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 61.95% vs -15.31% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.30",
          "val2": "-5.70",
          "chgp": "24.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.60",
          "val2": "-2.20",
          "chgp": "172.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.30",
          "val2": "-11.30",
          "chgp": "61.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-25,381.80%",
          "val2": "-34,549.90%",
          "chgp": "916.81%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -11.43% vs 1,650.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.94% vs -0.97% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.20",
          "val2": "7.00",
          "chgp": "-11.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.70",
          "val2": "-35.60",
          "chgp": "27.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.80",
          "chgp": "25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "0.10",
          "chgp": "-1,000.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-34.30",
          "val2": "-41.80",
          "chgp": "17.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,262.00%",
          "val2": "-6,009.00%",
          "chgp": "74.70%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.20

Operating Profit (PBDIT) excl Other Income

-4.30

-5.70

24.56%

Interest

0.20

Exceptional Items

1.60

-2.20

172.73%

Consolidate Net Profit

-4.30

-11.30

61.95%

Operating Profit Margin (Excl OI)

-25,381.80%

-34,549.90%

916.81%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -80.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 61.95% vs -15.31% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

6.20

7.00

-11.43%

Operating Profit (PBDIT) excl Other Income

-25.70

-35.60

27.81%

Interest

1.00

0.80

25.00%

Exceptional Items

-0.90

0.10

-1,000.00%

Consolidate Net Profit

-34.30

-41.80

17.94%

Operating Profit Margin (Excl OI)

-5,262.00%

-6,009.00%

74.70%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -11.43% vs 1,650.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 17.94% vs -0.97% in Dec 2023

All Annual Results

Company CV

About Scorpius Holdings, Inc.

Scorpius Holdings, Inc.

Pharmaceuticals & Biotechnology

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Company Coordinates

Company Details

627 DAVIS DRIVE, SUITE 400 , MORRISVILLE NC : 27560

Tel: 1 919 2407133

http://www.heatbio.com/

Registrar Details

Scorpius Holdings, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Scorpius Holdings, Inc.?

Watch in Real-Time

What does Scorpius Holdings, Inc. do?

Who are in the management team of Scorpius Holdings, Inc.?

Is Scorpius Holdings, Inc. overvalued or undervalued?

Is Scorpius Holdings, Inc. technically bullish or bearish?

Compare Scorpius Holdings, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Jun 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Scorpius Holdings, Inc.

Company Coordinates